Market Cap : 68.53 B | Enterprise Value : 63.67 B | PE Ratio : 12.55 | PB Ratio : 3.33 |
---|
NAS:REGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:REGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Regeneron Pharmaceuticals has the Profitability Rank of 9. It has a higher profitability and may stay that way.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Regeneron Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 was 45.74%. As of today, Regeneron Pharmaceuticals's Piotroski F-Score is 5.
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Regeneron Pharmaceuticals has the Profitability Rank of 9. It has a higher profitability and may stay that way.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Regeneron Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | 1306.9 | / | 2857.2 | |
= | 45.74 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Regeneron Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Regeneron Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Schleifer Leonard S | director, officer: President & CEO | 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Van Plew Daniel P | officer: EVP & General Mgr Industrial O | REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Yancopoulos George | director, officer: President and CSO | |
Murphy Andrew J | officer: EVP Research | REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Mccourt Marion | officer: SVP Commercial | C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Fenimore Christopher R. | officer: VP, Controller | REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Coles N Anthony | director | MORRIS CORP. CENTER I; BLDG. B; 4TH FLR. 300 INTERPACE PARKWAY PARSIPPANY NJ 07054 |
Zoghbi Huda Y | director | REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Bassler Bonnie L | director | REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Ingram Robert Alexander | director | 280 S. MANGUM STREET SUITE 350 DURHAM NC 27701 |
Sanofi | 10 percent owner | 54 RUE LA BOETIE PARIS I0 75008 |
Landry Robert E | officer: SVP Fin, Dep CFO | 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Tessier-lavigne Marc | director | 1 DNA WAY SOUTH SAN FRANCISCO CA 94080 |
Larosa Joseph J | officer: SVP Gen Counsel & Secretary | 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 |
Poon Christine A | director | C/O JOHNSON & JOHNSON ONE JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
From GuruFocus
Other Sources
By Zacks 2022-03-09
By Zacks 2022-03-29
By Zacks 2022-03-28
By Zacks 2022-04-01
By tipranks.com 2022-03-30
By Zacks 2022-03-10
By Zacks 2022-02-25
By Zacks 2022-02-14
By Zacks 2022-03-04
By Zacks 2022-02-18
By tipranks.com 2022-02-12
By Zacks 2022-03-03
By Zacks 2022-03-03